A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy

NCT07487896 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

440

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Esophageal Squamous Cell Carcinoma

Interventions

DRUG: YL201
DRUG: Paclitaxel
DRUG: Docetaxel
DRUG: Irinotecan

Sponsor

MediLink Therapeutics (Suzhou) Co., Ltd.